The investment bank said that Exagen is poised for growth with a differentiated autoimmune test that outperforms conventional biomarker-based tests.

The test was developed in collaboration with Eli Lilly and can be used with other clinical information to rule out Alzheimer's disease as the cause of cognitive decline.

The cash deal includes ambulatory outreach laboratory services in 13 states and includes patient service centers and in-office phlebotomy sites.

Genetic Signatures also reported second quarter sales on par with the prior-year-quarter, reflecting higher respiratory testing in the Australian winter.

The firm posted before the market open on Tuesday results that beat expectations, and it raised its full-year revenue and earnings guidance.

The firm's life sciences revenues rose 1 percent, while diagnostics revenues were up 2 percent and biotechnology revenues jumped 8 percent.

The CEO submitted claims with codes for services that were never performed and received payments from more than one source for the same test.

Last week, readers were most interested in a story about Waters acquiring BD's biosciences and diagnostics solutions business.

The partners intend to develop a point-of-care testing instrument that can be used to aid the diagnosis of cancers and other diseases.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

Oncologists were one of the few provider groups to register support for the FDA rule, reflecting the challenge of assessing ...

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.